These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 12435687)

  • 1. In vitro activity of micafungin (FK-463) against Candida spp.: microdilution, time-kill, and postantifungal-effect studies.
    Ernst EJ; Roling EE; Petzold CR; Keele DJ; Klepser ME
    Antimicrob Agents Chemother; 2002 Dec; 46(12):3846-53. PubMed ID: 12435687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp.
    Messer SA; Diekema DJ; Boyken L; Tendolkar S; Hollis RJ; Pfaller MA
    J Clin Microbiol; 2006 Feb; 44(2):324-6. PubMed ID: 16455878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro antifungal activity of FK463, a new water-soluble echinocandin-like lipopeptide.
    Mikamo H; Sato Y; Tamaya T
    J Antimicrob Chemother; 2000 Sep; 46(3):485-7. PubMed ID: 10980180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Postantifungal Effect of Micafungin against the Species Complexes of Candida albicans and Candida parapsilosis.
    Gil-Alonso S; Jauregizar N; Eraso E; Quindós G
    PLoS One; 2015; 10(7):e0132730. PubMed ID: 26168269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the Post-Antifungal Effect of Rezafungin and Micafungin against Candida albicans, Candida parapsilosis and Candida glabrata.
    Carvalhaes CG; Rhomberg PR; Pfaller MA; Locke JB; Castanheira M
    Mycoses; 2022 Nov; 65(11):1040-1044. PubMed ID: 35778886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Global surveillance of in vitro activity of micafungin against Candida: a comparison with caspofungin by CLSI-recommended methods.
    Pfaller MA; Boyken L; Hollis RJ; Messer SA; Tendolkar S; Diekema DJ
    J Clin Microbiol; 2006 Oct; 44(10):3533-8. PubMed ID: 17021079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterising the post-antifungal effects of micafungin against Candida albicans, Candida glabrata, Candida parapsilosis and Candida krusei isolates.
    Nguyen KT; Ta P; Hoang BT; Cheng S; Hao B; Nguyen MH; Clancy CJ
    Int J Antimicrob Agents; 2010 Jan; 35(1):80-4. PubMed ID: 19889519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of the growth medium on the in vitro antifungal activity of micafungin (FK-463) against clinical isolates of Candida dubliniensis.
    Müller FM; Kurzai O; Hacker J; Frosch M; Mühlschlegel F
    J Antimicrob Chemother; 2001 Nov; 48(5):713-5. PubMed ID: 11679561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative study of disc diffusion and microdilution methods in susceptibility testing of micafungin against Candida species.
    Ramírez M; Serrano MC; Castro C; López E; Almeida C; Fernández A; Romero A; Martín-Mazuelos E
    J Antimicrob Chemother; 2006 Oct; 58(4):861-3. PubMed ID: 16916868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activities of echinocandins against Candida krusei determined by three methods: MIC and minimal fungicidal concentration measurements and time-kill studies.
    Cantón E; Pemán J; Valentín A; Espinel-Ingroff A; Gobernado M
    Antimicrob Agents Chemother; 2009 Jul; 53(7):3108-11. PubMed ID: 19380590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of 50% human serum on the killing activity of micafungin against eight Candida species using time-kill methodology.
    Földi R; Szilágyi J; Kardos G; Berényi R; Kovács R; Majoros L
    Diagn Microbiol Infect Dis; 2012 Aug; 73(4):338-42. PubMed ID: 22726529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of endpoints for antifungal susceptibility determinations with LY303366.
    Klepser ME; Ernst EJ; Ernst ME; Messer SA; Pfaller MA
    Antimicrob Agents Chemother; 1998 Jun; 42(6):1387-91. PubMed ID: 9624481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates.
    Nguyen KT; Ta P; Hoang BT; Cheng S; Hao B; Nguyen MH; Clancy CJ
    Antimicrob Agents Chemother; 2009 Aug; 53(8):3347-52. PubMed ID: 19364856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin.
    Takakura S; Fujihara N; Saito T; Kudo T; Iinuma Y; Ichiyama S
    J Antimicrob Chemother; 2004 Feb; 53(2):283-9. PubMed ID: 14688039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods.
    Ernst EJ; Klepser ME; Ernst ME; Messer SA; Pfaller MA
    Diagn Microbiol Infect Dis; 1999 Feb; 33(2):75-80. PubMed ID: 10091029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature.
    Espinel-Ingroff A
    Rev Iberoam Micol; 2003 Dec; 20(4):121-36. PubMed ID: 15456349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antifungal dynamics of LY 303366, an investigational echinocandin B analog, against Candida ssp.
    Ernst ME; Klepser ME; Wolfe EJ; Pfaller MA
    Diagn Microbiol Infect Dis; 1996; 26(3-4):125-31. PubMed ID: 9078447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi.
    Tawara S; Ikeda F; Maki K; Morishita Y; Otomo K; Teratani N; Goto T; Tomishima M; Ohki H; Yamada A; Kawabata K; Takasugi H; Sakane K; Tanaka H; Matsumoto F; Kuwahara S
    Antimicrob Agents Chemother; 2000 Jan; 44(1):57-62. PubMed ID: 10602723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postantifungal effect of micafungin against Candida albicans, Candida dubliniensis and Candida africana in the presence and absence of serum.
    Kardos T; Saleh Q; Kovács R; Gesztelyi R; Kardos G; Bozó A; Tóth Z; Majoros L
    New Microbiol; 2017 Oct; 40(4):286-288. PubMed ID: 28994449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Candida and candidaemia. Susceptibility and epidemiology.
    Arendrup MC
    Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.